Eli Lilly Investors Seek Foundayo Weight Loss Pill Data
Investors seek Foundayo sales data despite its April launch. The firm faces high expectations for its obesity drugs amid shifting global pricing dynamics.
ELI LILLY & CO shares fell 19% this year as investors await first-quarter results and data on its new Foundayo weight-loss pill. Analysts forecast a 26% revenue rise driven by global demand for obesity treatments in the United States and abroad. Foundayo's early trajectory will signal if Lilly can maintain its lead against NOVO NORDISK A/S-B.
### Foundayo Launch Dynamics Lilly launched Foundayo in early April, meaning the drug's performance will not appear in the first-quarter financials reported Thursday morning. BMO Capital Markets analyst Evan Seigerman said it is too early to judge the launch strength just two weeks after the pill hit the market. Investors typically require five to six weeks of prescription data to determine a reliable sales trajectory.
